James Arthur Geraghty
Independent DirectorMr. James Arthur Geraghty, also known as Jim, J.D. M.S., serves as Member of the Advisory Board of Soleno Therapeutics, Inc. since January 2024. He served as Chairman of OMass Therapeutics Limited since May 2023 until January 2026. He was an Entrepreneur in Residence at TRV. From April 2011 until December 2012. He serves as Independent Non-Executive Director at Canbridge Limited since July 18, 2018. He serves as an Independent Non-Executive Director at CANbridge Life Sciences Ltd. since July 18, 2018. He has been an Independent Director of Voyager Therapeutics, Inc. since January 7, 2014. He has been Independent Non Executive Director at CANbridge Pharmaceuticals Inc. since July 18, 2018. He has been a Director at Fulcrum Therapeutics, Inc., since July 2016. He served as Independent Chairman of Orchard Therapeutics plc since May 2018 until January 24, 2024 and served as its Independent Director until January 24, 2024. He is the Chairman of the Board of Juniper Pharmaceuticals and is on the Board of Voyager Therapeutics. He served as an Interim Chief Business Officer of Voyager Therapeutics, Inc. He served as Senior Vice President of North America Strategy & Business Development at Sanofi S.A. from February 2011 to October 2013. Earlier, he held many roles at Genzyme Corporation from 1992 to 2011 most recently as Senior Vice President of International Development and an Executive Officer. He is an industry leader with strategic and leadership experience, including as a Senior Member of Executive Teams at biotechnology companies developing and commercializing innovative therapies. He served as Senior Vice President of North American Strategy & Business Development at Genzyme Corporation and served as its Senior Vice President since May 2003 and Vice President since May 2001. He joined Genzyme in 1992. He served as Vice President of Marketing & Strategic Planning at Baxter International Inc. He served as Vice President of Genzyme Oncology, Inc. (also known as Genzyme Molecular Oncology) since May 2001 and served as its Senior Vice President of International Development since January 2001. Mr. Geraghty worked at Genzyme. He served as the President of Genzyme Europe B.V. from 1998 to 2002 and served as its General Manager of its Cardiovascular Business from 2004 to 2008. He led Genzyme's acquisition of SangStat Medical Corporation in 2003. He served as the President and Chief Executive Officer of rEVO Biologics, Inc. (formerly, GTC Biotherapeutics Inc. and Genzyme Transgenics Corporation) from February 1993 to July 1998. He oversaw Genzyme's Humanitarian Assistance for Neglected Diseases program, under which it supported innovative therapeutic programs on a non-commercial basis. He served as Vice President of Marketing and Strategic Planning for Baxter and Caremark International. He was a Consultant on international health care strategy at Bain and Company. He was an Entrepreneur-in-Residence at Third Rock Ventures, LLC since May 14, 2013 until October 2016. He focused on creating companies dedicated to improving the lives of patients with rare genetic diseases and supporting existing portfolio companies in the rare disease space, such as Fulcrum. He served as Chairman of Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) since July 2013 until 2023 and had been its Director until March 27, 2023. He was Chairman of the Board at rEVO Biologics, Inc. since April 2014. He was Independent Chairman of the Board of Palvella Therapeutics, Inc. (Formerly, Pieris Pharmaceuticals, Inc.) since December 2017 and its Director since May 22, 2017 until December 13, 2024. He served as Chairman of the Board of Juniper Pharmaceuticals, Inc. since July 7, 2015 until August 14, 2018 and its Director since May 2015 until August 14, 2018. He served as the Chairman of rEVO Biologics, Inc. from January 1998 to July 2001. He has been a Director of Immunexcite, Inc. since March 30, 2016. He serves as a Director of MG Biotherapeutics LLC, Therapeutic Human Polyclonals, Inc., BIO Ventures for Global Health, Excigen Inc. and Myosix SA and as a Member of the Advisory Board of KBC Biotech Fund. He had been a Member of Advisory Board at CANbridge Life Sciences Ltd. since September 26, 2013. He served as a Trustee of Joslin Diabetes Center, Inc. since January 14, 2014. He served as a Director of bluebird bio, Inc. (Also known as Genetix Pharmaceuticals, Inc.). He served as an Independent Director of rEVO Biologics, Inc. from February 1993 to December 2, 2010. He holds a J.D. from Yale Law School in May 1980, an M.S. in Clinical Psychology from the University of Pennsylvania and a B.A. in Psychology and English from Georgetown University.
Positions
- Company NameFulcrum Therapeutics, Inc.Stock CodeFULCPositionIndependent DirectorColleagues
- ACAlexander C. SapirCEO, President & Director
- KHKathryn HavilandIndependent Chair of the Board
- AAAlan A. MussoCFO, Treasurer & Principal Accounting Officer
- CGCurtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- BEBradley E. BernsteinFounder
- MRMichael R. GreenFounder
- KDKatina DortonIndependent Director
- RKRachel K. KingIndependent Director
- Company NameVoyager Therapeutics, Inc.Stock CodeVYGRPositionIndependent DirectorColleagues
- AWAlfred W. SandrockCEO & Director
- MJMichael J. HigginsIndependent Chairman of the Board
- RSRobin SwartzPresident
- KBKrystof BankiewiczFounder
- MAMark A. KayFounder
- AQAmy QuinlanPrincipal Accounting Officer
- NVNancy VitaleIndependent Director
- GAGeorge A. ScangosIndependent Director
- JAJames Arthur GeraghtyIndependent Director
- Company NameCANbridge Pharmaceuticals Inc.Stock Code01228PositionIndependent Non-Executive DirectorColleagues
- QXQun XueFounder, Chairman of the Board, CEO & Member of Strategic Advisory Board
- LZLillian ZhangSenior Director & Head of Finance Operations and Controller
- JSJoe ShenChief Operating Officer
- QMQian MaVice President, Company Secretary & General Counsel
- CCChris ChenSenior Vice President of Human Resources
- RJRichard James GregoryIndependent Non-Executive Director
- PKPeng Kuan ChanIndependent Non-Executive Director
- JAJames Arthur GeraghtyIndependent Non-Executive Director
- MAMark Alan GoldbergMember of Strategic Advisory Board
